HormoneFDA Approved

Gonadorelin (GnRH)

Intravenous, Subcutaneous injection

Overview

A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone. Gonadorelin stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary when administered in a pulsatile fashion.

Mechanism of Action

Continuous or high-dose administration paradoxically downregulates GnRH receptors, suppressing gonadotropin secretion, a principle exploited by GnRH agonist therapeutics..

Research Summary & Key Findings

FDA-approved for diagnostic evaluation of hypothalamic-pituitary-gonadal axis function and for induction of ovulation. Pulsatile GnRH pump therapy successfully restores fertility in hypothalamic amenorrhea patients. The diagnostic test measures LH response to distinguish hypothalamic from pituitary causes of hypogonadism.

Clinical Status

FDA Approved

Gonadorelin (GnRH) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

IntravenousSubcutaneous injection

Related Peptides in Hormone

Find a Provider

Find a verified provider who offers Gonadorelin (GnRH) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Gonadorelin (GnRH).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.